Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore […]
Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, […]
Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014 May;21 Suppl 1:1-4. doi: 10.1111/jvh.12253. PMID: 24713003. Summary Chronic hepatitis C virus (HCV) infection leads to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The recent Global […]
Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. […]
Deelder W, Eustance J, Pingali P et al. Hepatitis C medicines and diagnostics in the context of HIV/HCV co-infection: A scoping report. UNITAID; 2013 Oct 1.
Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013 Jun;57(6):2164-70. doi: 10.1002/hep.26218. Epub 2013 May 6. PMID: 23280550; PMCID: PMC3763475. Summary Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and […]
Hamoudi W, Ali SA, Abdallat M, Estes CR, Razavi HA. HCV infection prevalence in a population recruited at health centers in Jordan. J Epidemiol Glob Health. 2013 Jun;3(2):67-71. doi: 10.1016/j.jegh.2013.02.003. Epub 2013 Mar 19. PMID: 23856567; PMCID: PMC7320397. Summary Background Jordan lacks statistical data regarding prevalence of HCV. Aim To determine the prevalence of HCV […]
El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012;15(5):887-96. doi: 10.3111/13696998.2012.681332. Epub 2012 May 24. PMID: 22458755. Summary Background Globally, hepatitis C virus (HCV) infects ~3% of the population. The objective of this study was to review published work […]
El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012 Mar;19(3):153-60. doi: 10.1111/j.1365-2893.2011.01563.x. Epub 2011 Dec 18. PMID: 22329369. Summary There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become […]
Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x. PMID: 21651700. Summary Background Hepatitis […]